Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors

Area of Science:

• Molecular Biology
• Drug Discovery
• Immunology

Background:

• Signal transducer and activator of transcription 3 (STAT3) signaling is implicated in cancer and inflammation.
• STAT3 inhibitors are a promising therapeutic strategy, but selectivity over STAT1 is critical due to their opposing roles.
• STAT1 and STAT3 have opposing functions in tumor cell apoptosis and immune cell polarization.

Purpose of the Study:

• To identify and optimize a selective STAT3 transcriptional activity inhibitor.
• To evaluate the compound's efficacy and specificity against STAT3 and STAT1 signaling pathways.
• To assess the compound's impact on T lymphocyte polarization.

Main Methods:

• Structure-based virtual screening was employed to identify potential STAT3 inhibitors.
• Luciferase reporter assays were used to measure STAT3 and STAT1 signaling activity.
• A hit compound was optimized, leading to the identification of compound 23.

Main Results:

• Compound 23 selectively inhibits STAT3 signaling, impacting tumor cell growth and survival.
• The compound demonstrated minimal inhibition of STAT1 signaling, ensuring selectivity.
• Compound 23 modulated T lymphocyte polarization, inhibiting Th17 and Treg differentiation while sparing Th1 differentiation.

Conclusions:

• A novel, selective STAT3 inhibitor (compound 23) was successfully developed.
• This inhibitor shows therapeutic potential for STAT3-driven cancers and inflammatory conditions.
• The findings highlight the importance of STAT3/STAT1 selectivity in developing targeted therapies.